The FDA’s clearance of this expanded label enables access to Deep TMS™ for the critically important adolescent patient ...
The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...
To provide some solid data, the authors of the new study gave LSD to a group of patients in New Zealand, and instructed them ...
New research suggests that microdosing a popular psychedelic may provide relief for people struggling with major depressive ...
Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...
University of Auckland researchers report that an 8-week, twice-weekly LSD microdosing regimen for major depressive disorder ...
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
Everyday Health on MSN
Your Financial Guide to Living With Major Depressive Disorder
Psychotherapy can have high up-front costs, says Dr. Smoski, but there are some studies showing it can be cost effective, compared to medication, in the long run. Therapy sessions can range from $100 ...
Background: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major ...
The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...
The FDA has approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for treating major depressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback